<DOC>
	<DOCNO>NCT01868243</DOCNO>
	<brief_summary>DAWA phase 2 , prospective , open-label , randomize , pilot study . The main variable observe study intracardiac thrombus . There formal primary secondary clinical efﬁcacy safety outcomes pilot study .</brief_summary>
	<brief_title>Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement Atrial Fibrillation Postoperatively</brief_title>
	<detailed_description>Mortality morbidity event ( reversible ischemic neurological deficit , ischemic hemorrhagic stroke , systemic embolism , bleeding , prosthesis valve thrombosis death ) evaluate exploratory manner . The detail trial design previously described.8 The trial protocol approve local ethic research committee city Salvador-Brazil , write informed consent obtain patient . An independent data safety monitor board closely monitor trial . All member contribute interpretation result , write first version manuscript approve version , make decision submit manuscript publication , vouch accuracy completeness data report fidelity article study protocol . Patients eligible inclusion study 18 64 year old , underwent mitral and/or aortic bioprosthesis valve replacement least 3 month prior enter study document AF postoperatively addition exclusion atrial thrombus valve prosthesis thrombosis transesophageal echocardiography ( TEE ) . Non-contrast brain compute tomography ( CT ) without hemorrhage finding acute cerebral infarction last 2 day screen also necessary . Patients randomly assign receive dabigatran warfarin computer generate list random number perform 1:1 ratio group . Following , allocation sequence conceal researcher enrol participant sequentially number , opaque , black , sealed envelope . After randomization , patient study visit schedule 7 day ( via telephone ) 30 day ( personally ) monthly follow-up 90 day . After , non-contrast brain CT TEE repeat . The former execute document possible cerebral event clinical expression latter analyze incidence intracardiac thrombus , new dense spontaneous echo contrast ( SEC ) resolution , addition thrombosis dysfunction valvular prosthesis .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Age 18 64 year entry 2 . Patients mitral and/or aorthic valve bioprosthesis least 3 month postoperatively 3 . There 12lead electrocardiogram document AF day screen randomization ; 24hour Holter electrocardiogram record show AF episode postoperatively 4 . Brain compute tomography scan without hemorrhage finding acute cerebral infarction last 2 day screen 5 . Exclusion atrial thrombus valve prosthesis thrombosis transesophageal echocardiograph last 2 day screen 6 . Written , inform consent 1 . Previous hemorrhagic stroke 2 . Ischemic stroke last 6 month 3 . Severe renal impairment ( creatinine clearance rate &lt; 30 ml/min ) 4 . Active liver disease ( etiology ) 5 . Concomitant use antiplatelet ( aspirin , clopidogrel , prasugrel , ticagrelor , ticlopidine , etc ) 6 . Increased risk bleeding ( congenital acquire ) 7 . Uncontrolled hypertension 8 . Gastrointestinal hemorrhage within past year 9 . Anemia ( hemoglobin level &lt; 10 g/dL ) thrombocytopenia ( platelet count &lt; 100 × 109/L ) 10 . Active infective endocarditis 11 . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Bioprosthesis</keyword>
	<keyword>Stroke</keyword>
	<keyword>Dabigatran</keyword>
	<keyword>Warfarin</keyword>
</DOC>